AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25576687
Drug: Metoclopramide nasal
RxNorm normalized name: metoclopramide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide nasal spray 10 mg
Trial: 24372829
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide 10 mg
Trial: 15920197
Drug: Conventional propofol-lidocaine
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional propofol-lidocaine mixtures with 20 mg lidocaine
Trial: 15920197
Drug: Propofol-MCT/LCT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-MCT/LCT with 20 mg lidocaine
Trial: 12727037
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release morphine sulfate (MSIR)
Trial: 9366661
Drug: Assertive Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive Community Treatment (ACT) program
Trial: 1552711
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) therapy
Trial: 1552711
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg orally) after baseline values
Trial: 1552711
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg orally) after correction of hematocrit
Trial: 29753637
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg administered orally once daily (with dose reductions to 40 mg or 20 mg for adverse events)
Trial: 29753637
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg administered orally once daily
Trial: 24237610
Drug: EP42675 (1-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP42675 (1-10 mg, single ascending doses)
Trial: 24237610
Drug: EP42675 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP42675 (5 mg, single dose) + Aspirin (100 mg) + Clopidogrel (75 mg)
Trial: 24237610
Drug: EP42675 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP42675 (5 mg, second dose) + UFH (30 or 60 IU kg(‐1))
Trial: 24237610
Drug: EP42675 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP42675 (5 mg, single dose)
Trial: 15959362
Drug: Control (nonoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nonoperative treatment)
Trial: 12030727
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 6 mg
Trial: 9849982
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml intradermal (i.d.) PVRV
Trial: 9849982
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml intramuscular (i.m.) PVRV
Trial: 7852216
Drug: recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant erythropoietin (rhEPO) therapy
Trial: 3214852
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1.0 mM copper and 2.0 mM hexetidine
Trial: 23747945
Drug: 1.0mg fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0mg fluoride tablet daily
Trial: 16709309
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Atorvastatin + Fenofibrate)
Trial: 16709309
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and Combination treatment
Trial: 8492101
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b therapy for 1 year
Trial: 8492101
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy for 1 year
Trial: 6428307
Drug: Rosoxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosoxacin (300 mg oral dose)
Trial: 6428307
Drug: Ampicillin (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (3.5 g) plus Probenecid (1 g)
Trial: 22752356
Drug: No propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No propofol infusion
Trial: 17493508
Drug: Cilazapril 2.5-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5-5.0 mg/day (n=70)
Trial: 17493508
Drug: Enalapril 10-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-20 mg/day (n=82)
Trial: 17493508
Drug: Perindopril 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4-8 mg/day (n=73)
Trial: 17493508
Drug: Imidapril 10-20
RxNorm normalized name: imidapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril 10-20 mg/day (n=76)
Trial: 17375736
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization (OD) for milk allergy
Trial: 17375736
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization (OD) for egg allergy
Trial: 15037408
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHEA
Trial: 8958491
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% with adrenaline 5 micrograms mL‐1 (group II)
Trial: 8958491
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% with adrenaline 1.66 micrograms mL‐1 (group III)
Trial: 3883504
Drug: oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral etoposide (VePe-sid) 300 mg/m2 on days 1 and 2 for 6 cycles
Trial: 3883504
Drug: oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral etoposide plus cyclophosphamide 300 mg/m2 IV on days 1 and 2 for 6 cycles
Trial: 3883504
Drug: oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral etoposide
Trial: 31415133
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment (3 hours paediatrician + 4 hours dietician)
Trial: 31415133
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment (35 hours with a multidisciplinary team)
Trial: 25735985
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO2) at 2.4 standard atmosphere, FI O2 = 1.0, for 90 minutes
Trial: 21061834
Drug: Olmesartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (40 mg/day)
Trial: 20137542
Drug: Telmisartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (80 mg/day)
Trial: 12908850
Drug: Rebif 44
RxNorm normalized name: Rebif 44 MCG in 0.5 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebif 44 microg three times weekly
Trial: 10999649
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal GTN therapy (0.6 mg/hour)
Trial: 10999649
Drug: Sublingual GTN
RxNorm normalized name: GTN Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual GTN (0.6 mg)
Trial: 9360173
Drug: Manual border
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual border tracing by two observers or twice by the same observer
Trial: 31522033
Drug: Brivanib 800
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib 800 mg daily
Trial: 11794192
Drug: Warfarin (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted to produce an INR of 1.4 to 2.8)
Trial: 22551105
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg per day)
Trial: 31231918
Drug: Sufentanil 0.2
RxNorm normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.2 μg/kg (Group A)
Trial: 31231918
Drug: Sufentanil 0.1
RxNorm normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.1 μg/kg (Group B)
Trial: 23624890
Drug: Once-daily (QD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (QD) oral mesalazine (1.5 to 2.25 g/d)
Trial: 23624890
Drug: Three-times-daily (TID)
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times-daily (TID) oral mesalazine
Trial: 16580905
Drug: Acetaminophen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1 g) + Tropisetron (5 mg)
Trial: 16580905
Drug: Acetaminophen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1 g) + Granisetron (3 mg)
Trial: 16580905
Drug: Acetaminophen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1 g) + Placebo (saline solution)
Trial: 12751271
Drug: Valdecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (40 mg bid)
Trial: 12751271
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg tid)
Trial: 9473972
Drug: Continuous concurrent
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous concurrent visual feedback during practice
Trial: 6327758
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (400 mg)
Trial: 3214945
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg)
Trial: 29551675
Drug: ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticagrelor 90 mg twice per day for 2 years
Trial: 29551675
Drug: aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 81 mg twice per day for 2 years
Trial: 26934973
Drug: Daily Engagement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Engagement of Meaningful Activities (DEMA)
Trial: 24507460
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (4,000 IU/d)
Trial: 24507460
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D3 (600 IU/d)
Trial: 23059774
Drug: Bevacizumab (BV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BV) maintenance therapy after induction with carboplatin and paclitaxel (CP)
Trial: 17609910
Drug: Rukuaixiao Tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rukuaixiao Tablet, 4 tablets orally thrice a day for 4 months
Trial: 7882099
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg) parenterally twice daily for 10 days
Trial: 2239131
Drug: Diazepam (rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (rectal solution every 12 hours when temperature is 38.5 degrees C or more)
Trial: 2239131
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (suppositories at times of fever)
Trial: 6787702
Drug: Auranofin (AF)
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auranofin (AF) 6 mg per day
Trial: 25644033
Drug: Tramadol-acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol-acetaminophen
Trial: 24308613
Drug: i.v. normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. normal saline (20 mL/kg) plus observation
Trial: 22049950
Drug: Peppered injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppered injections
Trial: 18832042
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 40 microg PGE1
Trial: 18832042
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no trial medication)
Trial: 10087818
Drug: Continuous PKF
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous PKF (propofol 2‐10 mg.kg‐1.h‐1, ketamine 240 micrograms.kg‐1.h‐1 and fentanyl 0.4 microgram.kg‐1.h‐1)
Trial: 7553406
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg, single intravenous dose)
Trial: 7553406
Drug: Metoclopramide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (2 mg/kg, multiple doses)
Trial: 2111768
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) discontinuation
Trial: 2111768
Drug: Valproate (VPA)
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate (VPA) discontinuation
Trial: 2111768
Drug: Phenytoin (PHT)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin (PHT) discontinuation
Trial: 2111768
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stable therapy)
Trial: 415439
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 5-10 mmol phosphate (155-310 mg phosphorus) per 1000 kcal of nutrient solution during parenteral nutrition.
Trial: 415439
Drug: Increased phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased phosphate dosage for hypophosphatemic patients with acute renal insufficiency.
Trial: 415439
Drug: Serum phosphate
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum phosphate determination at the start of parenteral nutrition and every second day during the first week.
Trial: 415439
Drug: Serum phosphate
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum phosphate determination twice weekly after the first week of parenteral nutrition.
Trial: 21463068
Drug: Concurrent Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent Alcohol Dependence (AD)
Trial: 16886934
Drug: Concurrent stress-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent stress-management therapy
Trial: 16886934
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication and placebo (irrespective of drug condition)
Trial: 16886934
Drug: Neurologists' ratings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurologists' ratings of improvement, participants' reports of improvement, daily headache recordings
Trial: 15174784
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 200 microg twice daily
Trial: 15174784
Drug: Treatment-free period
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-free period
Trial: 9475646
Drug: Placebo (cellulose‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose‐based placebo pills once a day for 2 weeks)
Trial: 8560135
Drug: L-dopa 100-200
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa 100-200 mg
Trial: 21930686
Drug: IMM-101 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMM-101 0.1 mg (1 mg/ml)
Trial: 21930686
Drug: IMM-101 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMM-101 0.5 mg (5 mg/ml)
Trial: 21930686
Drug: IMM-101 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMM-101 1.0 mg (10 mg/ml)
Trial: 21930686
Drug: IMM-101 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMM-101 (all doses)
Trial: 17655512
Drug: Alprazolam ODT
RxNorm normalized name: Alprazolam Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam ODT 1.0 mg under fasting conditions
Trial: 17655512
Drug: Alprazolam ODT
RxNorm normalized name: Alprazolam Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam ODT 1.0 mg after a standard high-fat breakfast
Trial: 12151926
Drug: ANH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANH group (5-8 ml/kg of blood withdrawn before systemic heparinization and replaced with colloid solutions)
Trial: 20425223
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator (rt-PA) administered within 4.5 hours of symptom onset
Trial: 20425223
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator (rt-PA) administered within 3 hours of symptom onset
Trial: 17406114
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of treatment modalities
Trial: 15750363
Drug: Herbal supplement
RxNorm normalized name: LYDIA PINKHAM Herbal Supplement Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal supplement for a 2-week period
Trial: 15750363
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no herbal supplement)
Trial: 11902251
Drug: Low-dose prostacyclin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prostacyclin (2 ng/kg/min) added to the standard anesthetic protocol, started immediately before surgery and continued for a maximum of 48 hours.
Trial: 11902251
Drug: Low-dose prostacyclin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prostacyclin (2 ng/kg/min)
Trial: 31401532
Drug: Tobacco/Menthol 36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco/Menthol 36 mg/ml ECIG
Trial: 31401532
Drug: Tobacco/Menthol 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco/Menthol 0 mg/ml ECIG
Trial: 31401532
Drug: 36 mg/ml
RxNorm normalized name: iodine 36 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 mg/ml ECIG
Trial: 29106497
Drug: Cumulative doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative doxorubicin equivalent dose ≥268 mg/m2
Trial: 10568767
Drug: Vaccinia-vectored vaccine;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinia-vectored vaccine; subcutaneous inoculation of approximately 10^7 plaque-forming units; administered in two doses at 4-week intervals.
Trial: 10568767
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group); administered in a double-blinded manner.
Trial: 3594319
Drug: No pre-medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre-medication (control)
Trial: 30541643
Drug: Selective brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective brain hypothermia (SBH) treatment
Trial: 18073554
Drug: Medium-dose smoked
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose smoked cannabis (4% 9-delta-tetrahydrocannabinol)
Trial: 18073554
Drug: High-dose smoked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose smoked cannabis (8% 9-delta-tetrahydrocannabinol)
Trial: 18073554
Drug: Low-dose smoked
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose smoked cannabis (2% 9-delta-tetrahydrocannabinol)
Trial: 18073554
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of smoked cannabis
Trial: 12351557
Drug: E(2) 2
RxNorm normalized name: (E)-2-butenedioic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2) 2 mg/day plus NETA 1 mg/day
Trial: 27296057
Drug: Calcium-Vitamin D
RxNorm normalized name: Calcium-Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-Vitamin D (1000 mg calcium + 5000 IU vitamin D3)
Trial: 27296057
Drug: Calcium-alone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-alone (1000 mg)